Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
---|---|---|---|---|
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
US7169780 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2023
(7 months from now) | |
US7754731 | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Mar, 2029
(6 years from now) | |
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
US7217713 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 months ago) | |
US7435734 | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Oct, 2022
(3 months ago) | |
US7435734
(Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 months from now) | |
US7217713
(Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2023
(2 months from now) | |
US7169780
(Pediatric) | MERCK SHARP DOHME | N-substituted hydroxypyrimidinone carboxamide inhibitors of HIV integrase |
Apr, 2024
(1 year, 1 month from now) | |
US7754731
(Pediatric) | MERCK SHARP DOHME | Potassium salt of an HIV integrase inhibitor |
Sep, 2029
(6 years from now) | |
US9649311 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Oct, 2030
(7 years from now) | |
US9649311
(Pediatric) | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Apr, 2031
(8 years from now) | |
US10772888 | MERCK SHARP DOHME | Solid pharmaceutical compositions containing an integrase inhibitor |
Mar, 2032
(9 years from now) |
Market Authorisation Date: 20 December, 2013
Treatment: Treatment of hiv infection; Treatment of hiv-1 infection
Dosage: POWDER;ORAL
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic